Glaukos (NYSE:GKOS) Research Coverage Started at UBS Group

UBS Group assumed coverage on shares of Glaukos (NYSE:GKOS) in a report released on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $182.00 target price on the medical instruments supplier’s stock.

GKOS has been the topic of several other research reports. BTIG Research increased their target price on Glaukos from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Wells Fargo & Company raised their price target on Glaukos from $135.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Truist Financial raised their price target on Glaukos from $145.00 to $152.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler set a $140.00 price target on Glaukos in a report on Thursday, October 17th. Finally, Stephens upgraded Glaukos to a “strong-buy” rating in a report on Monday, December 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $140.00.

Glaukos Price Performance

Shares of GKOS stock opened at $140.28 on Friday. The stock’s fifty day moving average is $135.17 and its 200-day moving average is $125.97. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The stock has a market capitalization of $7.73 billion, a PE ratio of -46.45 and a beta of 1.03. Glaukos has a 52 week low of $59.58 and a 52 week high of $146.86.

Glaukos (NYSE:GKOS) last announced its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analysts’ expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business’s revenue for the quarter was up 23.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.50) earnings per share. Equities research analysts expect that Glaukos will post -1.89 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other news, COO Joseph E. Gilliam sold 2,275 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now owns 102,169 shares of the company’s stock, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of hedge funds have recently modified their holdings of GKOS. Cetera Advisors LLC acquired a new stake in shares of Glaukos during the first quarter worth about $213,000. LVW Advisors LLC acquired a new stake in shares of Glaukos during the second quarter worth about $213,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Glaukos during the second quarter worth about $229,000. Assenagon Asset Management S.A. acquired a new stake in shares of Glaukos during the second quarter worth about $6,832,000. Finally, Raymond James & Associates raised its position in shares of Glaukos by 23.2% during the second quarter. Raymond James & Associates now owns 13,017 shares of the medical instruments supplier’s stock worth $1,541,000 after purchasing an additional 2,452 shares during the period. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.